Valerio Therapeutics Société anonyme (EPA:ALVIO)

Market Cap	82.91M +753.4%
Revenue (ttm)	2.57M +43.5%
Net Income	-4.90M
EPS	-0.02
Shares Out	499.45M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,242
Average Volume	240,544
Open	0.1660
Previous Close	0.1660
Day's Range	0.1660 - 0.1670
52-Week Range	0.0422 - 0.3100
Beta	1.76
RSI	65.25
Earnings Date	Jun 26, 2026

About EPA:ALVIO

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops developing VIO-01, which is in Phase 1/2 of the VIO-01 clinical study, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; and PlatON, generates DecoyTAC combining DNA decoy molecules capable of cell penetration with a linker+E3 ligand. It also develops V-body platform, a bis...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 25
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALVIO

Financial Performance

In 2025, EPA:ALVIO's revenue was 2.57 million, an increase of 43.50% compared to the previous year's 1.79 million. Losses were -4.90 million, -79.53% less than in 2024.